The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 4 January 2005, www.theannals.com, DOI 10.1345/aph.1E179.
 The Annals of Pharmacotherapy: Vol. 39, No. 2, pp. 361-364. DOI 10.1345/aph.1E179
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elbe, D. H.
Right arrow Articles by Chang, S. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elbe, D. H.
Right arrow Articles by Chang, S. W

Moxifloxacin–Warfarin Interaction: A Series of Five Case Reports

Dean HT Elbe, BSc(Pharm) BCPP

Clinical Pharmacist, Department of Pharmacy, The Richmond Hospital, Richmond, British Columbia, Canada

Sandra W Chang, BSc(Pharm)

Clinical Pharmacist, Department of Pharmacy, The Richmond Hospital

Reprints: Dean Elbe, Department of Pharmacy, The Richmond Hospital, 7000 Westminster Hwy., Richmond, British Columbia V6X 1A2, Canada, fax 604/244-5195, dean.elbe{at}vch.ca

OBJECTIVE: To report 5 cases of a moxifloxacin–warfarin drug interaction, all resulting in elevated international normalized ratios (INRs) and clinically significant hemorrhage in one case.

CASE SUMMARIES: Between January 2002 and January 2004, 4 men and 1 woman (age range 63–92 y) were retrospectively identified as having significantly elevated INR results shortly after being prescribed moxifloxacin with concomitant warfarin therapy.

DISCUSSION: This is the second series of case reports describing an interaction between warfarin and moxifloxacin. The current moxifloxacin product monograph indicates this drug has no significant effect on the pharmacokinetics of R- or S-warfarin or the prothrombin time (INR). A moxifloxacin–warfarin interaction probably led to prolonged hospitalization in 2 cases and significant gastrointestinal hemorrhage in one case. In 3 of the 5 cases, a moxifloxacin–warfarin interaction was assessed as probable, and in the remaining 2 cases, a moxifloxacin–warfarin interaction was assessed as possible by use of the Naranjo probability scale.

CONCLUSIONS: Healthcare professionals should consider moxifloxacin for the potential to interact with warfarin. Routine, frequent INR monitoring for patients previously stabilized on warfarin during initiation and discontinuation of moxifloxacin may help detect this potential interaction.

Key Words: drug interaction, international normalized ratio, moxifloxacin, warfarin

Published Online, January 4, 2005. www.theannals.com, DOI 10.1345/aph.1E179


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
D. N Carroll and D. G Carroll
Interactions Between Warfarin and Three Commonly Prescribed Fluoroquinolones
Ann. Pharmacother., May 1, 2008; 42(5): 680 - 685.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. P. Riechelmann, I. F. Tannock, L. Wang, E. D. Saad, N. A. Taback, and M. K. Krzyzanowska
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
J Natl Cancer Inst, April 18, 2007; 99(8): 592 - 600.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.